Where they stand: GLP-1 weight-loss drugs
Ozempic, Wegovy, Zepbound and the new Medicare coverage push. The movement is split: tool, crutch, or trap?
Each entry is that person's stated position, linked to the sourced page. This is a chronicle of views, not medical advice.
| Person | Position | |
|---|---|---|
| Robert F. Kennedy Jr. | No stated position on our record | |
| Dr. Mehmet Oz | Recommends GLP-1 medications for eligible seniors | |
| Dr. Marty Makary | No stated position on our record | |
| Dr. Jay Bhattacharya | No stated position on our record | |
| Dr. Casey Means | Warns Weight-loss drugs as a first-line answer (e.g., Ozempic for kids) | |
| Dr. Vinay Prasad | No stated position on our record | |
| Calley Means | Warns Ozempic as a substitute for root-cause fixes | |
| Dr. Mark Hyman | No stated position on our record | |
| Dr. Robert Lustig | Warns GLP-1 Drugs (Ozempic, Wegovy) as the Solution | |
| Gary Taubes | Warns Long-term unknowns of GLP-1 drugs | |
| Jillian Michaels | Warns GLP-1/Ozempic/Mounjaro as casual weight-loss tools Warns GLP-1 side effects and long-term risk claims | |
| Max Lugavere | No stated position on our record | |
| Vani Hari | No stated position on our record | |